{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:48:15Z","timestamp":1791809295584,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate early morphological changes following intravitreal aflibercept 8\u2009mg in treatment-na\u00efve neovascular age-related macular degeneration (nAMD) using artificial intelligence (AI)-assisted optical coherence tomography (OCT) segmentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty eyes with treatment-na\u00efve subfoveal nAMD received three monthly aflibercept 8\u2009mg injections. OCT scans were obtained at baseline and days 1, 7, 14, 30, 60, and 90. AI-based segmentation software (Fluid Monitor, RetInSight GmbH) quantified intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) volumes in the central 6-mm area. Morphologic changes were correlated with best-corrected visual acuity (BCVA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IRF, SRF, and PED showed distinct reduction patterns. In eyes with IRF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922), mean volume decreased by 65% at day 1, 94% at day 14, and 96% at day 90 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Among eyes with SRF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928), SRF volume decreased by 18%, 84%, and 99% at days 1, 14, and 90, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.002). PED volume declined more gradually among affected eyes (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923), with mean reductions of 7% at day 1, 34% by day 14, and 53% by day 90 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.023). BCVA improved from 51.8\u2009\u00b1\u200914.4 to 62.6\u2009\u00b1\u200914.4 ETDRS letters by day 90 (mean gain +\u200910.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Multivariate regression identified a significant association between IRF reduction at day 14 and BCVA gain at day 90 (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u2009=\u2009\u22120.018,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aflibercept 8\u2009mg induced rapid, compartment-specific morphologic responses in treatment-na\u00efve nAMD, with early IRF resolution and significant BCVA improvement. AI-assisted analysis provided detailed pharmacodynamic insights and may support individualised treatment strategies during the loading phase.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04319-1","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:59:43Z","timestamp":1772031583000},"page":"979-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AI-assisted analysis of early fluid dynamics following aflibercept 8\u2009mg in treatment-na\u00efve neovascular AMD"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-5348","authenticated-orcid":false,"given":"Daniele","family":"Veritti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-5073","authenticated-orcid":false,"given":"Valentina","family":"Sarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia Amelia","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-141X","authenticated-orcid":false,"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"4319_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000337154","volume":"227","author":"D Veritti","year":"2012","unstructured":"Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica. 2012;227:11\u201320.","journal-title":"Ophthalmologica"},{"key":"4319_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/jcm11020325","volume":"11","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, Lanzetta P. Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-Analysis, and meta-Regression. J Clin Med. 2022;11:325.","journal-title":"J Clin Med"},{"key":"4319_CR3","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/bjophthalmol-2013-303394","volume":"97","author":"P Lanzetta","year":"2013","unstructured":"Lanzetta P, Mitchell P, Wolf S, Veritti D. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Br J Ophthalmol. 2013;97:1497\u2013507.","journal-title":"Br J Ophthalmol"},{"key":"4319_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1097\/IAE.0000000000002299","volume":"39","author":"D Veritti","year":"2019","unstructured":"Veritti D, Sarao V, Missiroli F, Ricci F, Lanzetta P. Twelve-month outcomes of intravitreal aflibercept for neovascular age-related macular degeneration: fixed versus as-needed dosing. Retina. 2019;39:2077\u201383.","journal-title":"Retina"},{"key":"4319_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5301\/ejo.5000880","volume":"27","author":"D Veritti","year":"2017","unstructured":"Veritti D, Sarao V, Parravano M, Arias L, Varano M, Lanzetta P. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. Eur J Ophthalmol. 2017;27:74\u201379.","journal-title":"Eur J Ophthalmol"},{"key":"4319_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IAE.0000000000000751","volume":"36","author":"V Sarao","year":"2016","unstructured":"Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P. Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. 2016;36:770\u20137.","journal-title":"Retina"},{"key":"4319_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pharmaceutics14020265","volume":"14","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Gorni G, Lanzetta P. Anti-VEGF drugs dynamics: relevance for clinical practice. Pharmaceutics. 2022;14:265.","journal-title":"Pharmaceutics"},{"key":"4319_CR8","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s00417-025-06847-0","volume":"263","author":"D Veritti","year":"2025","unstructured":"Veritti D, Sarao V, Lanzetta P. Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance. Graefes Arch Clin Exp Ophthalmology. 2025;263:2985\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmology"},{"key":"4319_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/pharmaceutics15051416","volume":"15","author":"D Veritti","year":"2023","unstructured":"Veritti D, Sarao V, Di Bin F, Lanzetta P. Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics. 2023;15:1416.","journal-title":"Pharmaceutics"},{"key":"4319_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"4319_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10384-025-01229-9","volume":"69","author":"H Matsumoto","year":"2025","unstructured":"Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-na\u00efve neovascular age- related macular degeneration. Jpn J Ophthalmol. 2025;69:911\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"4319_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41433-025-03765-7","volume":"39","author":"V Sarao","year":"2025","unstructured":"Sarao V, Veritti D, Bonini F, Martin AA, Lanzetta P. Early intraocular pressure dynamics following aflibercept 8\u2009mg versus aflibercept 2\u2009mg: a propensity score-matched analysis. Eye (Lond). 2025;39:1933\u20139.","journal-title":"Eye (Lond)"},{"key":"4319_CR13","first-page":"915","volume":"9","author":"JG Fein","year":"2025","unstructured":"Fein JG, Vakharia PS, Chous AP, Desai R, Silva FQ, Reed K, et al. Clinical outcomes in neovascular age-related macular degeneration with aflibercept 8 mg in the phase II CANDELA study. Ophthalmol. Retina. 2025;9:915\u20138.","journal-title":"Retina"},{"key":"4319_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","volume":"14","author":"P Wojciechowski","year":"2025","unstructured":"Wojciechowski P, Wdowiak M, Panek M, Lunk I, Carrasco J, Zhang X, et al. Efficacy, safety, and injection frequency with novel aflibercept 8 mg in neovascular age-related macular degeneration: a comparison with existing anti-VEGF regimens using a Bayesian network meta-analysis. Ophthalmol Ther. 2025;14:733\u201353.","journal-title":"Ophthalmol Ther"},{"key":"4319_CR15","first-page":"206","volume":"56","author":"B Momenaei","year":"2025","unstructured":"Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of intravitreal aflibercept 8 mg in eyes with neovascular age-related macular degeneration previously treated with faricimab. Ophthalmic Surg Lasers Imaging. Retina. 2025;56:206\u201311.","journal-title":"Retina"},{"key":"4319_CR16","first-page":"438","volume":"18","author":"S Hosoda","year":"2025","unstructured":"Hosoda S, Sakurada Y, Fukuda Y, Kotoda Y, Kikushima W, Kashiwagi K. Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8 mg for treatment-na\u00efve exudative age-related macular degeneration. Pharm (Basel). 2025;18:438.","journal-title":"Pharm (Basel)"},{"key":"4319_CR17","first-page":"e00209","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10:e00209.","journal-title":"BMJ Open Ophthalmol"},{"key":"4319_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","volume":"9","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GCS, Mohan N, Srivastava SK, Kaiser PK, Sastry A, et al. Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retin. 2025;9:756\u201366.","journal-title":"Ophthalmol Retin"},{"key":"4319_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00417-023-06245-4","volume":"262","author":"D Veritti","year":"2024","unstructured":"Veritti D, Rubinato L, Sarao V, De Nardin A, Foresti GL, Lanzetta P. Behind the mask: a critical perspective on the ethical, moral, and legal implications of AI in ophthalmology. Graefes Arch Clin Exp Ophthalmol. 2024;262:975\u201382.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4319_CR20","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s40123-024-01005-x","volume":"13","author":"D Veritti","year":"2024","unstructured":"Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P. Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes. Ophthalmol Ther. 2024;13:2813\u201324.","journal-title":"Ophthalmol Ther"},{"key":"4319_CR21","doi-asserted-by":"publisher","first-page":"e001411","DOI":"10.1136\/bmjophth-2023-001411","volume":"8","author":"V Sarao","year":"2023","unstructured":"Sarao V, Veritti D, De Nardin A, Misciagna M, Foresti G, Lanzetta P. Explainable artificial intelligence model for the detection of geographic atrophy using colour retinal photographs. BMJ Open Ophthalmol. 2023;8:e001411.","journal-title":"BMJ Open Ophthalmol"},{"key":"4319_CR22","doi-asserted-by":"publisher","first-page":"e002176","DOI":"10.1136\/bmjophth-2025-002176","volume":"10","author":"M Hafner","year":"2025","unstructured":"Hafner M, Asani B, Eckardt F, Liesenhoff C, Kufner A, Siedlecki J, et al. Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration. BMJ Open Ophthalmol. 2025;10:e002176.","journal-title":"BMJ Open Ophthalmol"},{"key":"4319_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00665-6","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM. Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Na\u00efve neovascular AMD: AI-assisted fluid volume analysis. Int J Retin Vitreous. 2025;11:42.","journal-title":"Int J Retin Vitreous"},{"key":"4319_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000003557","volume":"42","author":"BS Gerendas","year":"2022","unstructured":"Gerendas BS, Sadeghipour A, Michl M, Goldbach F, Mylonas G, Gruber A, et al. Validation of an automated fluid algorithm on real-world data of neovascular age-related macular degeneration over five years. Retina. 2022;42:1673\u201382.","journal-title":"Retina"},{"key":"4319_CR25","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunovi\u0107 H. Application of automated quantification of fluid volumes to anti\u2013VEGF therapy of neovascular age-related macular degeneration. Ophthalmology. 2020;127:1211\u20139.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04319-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:29:07Z","timestamp":1778488147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04319-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4319"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04319-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DV is consultant for Bayer, Novartis, Roche; VS is consultant for Bayer, I-Care, Roche; AAM and FB declare no conflict of interests; PL is consultant for Aerie, Allergan, Annexon, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, EyeBio, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}